MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel

The results of a Phase II trial of reduced-glycerin 1% tenofovir gel among men who have sex with men and transgender women, published in Clinical Infectious Diseases, found that rectal application of the gel was safe and acceptable. Adherence and reported likelihood of future use were similar for intermittent use of the gel and a daily oral PrEP regimen, but lower for the daily gel regimen.

Length: 
1 page
Year: 
2016
Organization: 
Microbicide Trials Network
Languages: 
English
Author(s): 
Cranston, RD, Lama JR, Richardson BA, et al. for the MTN-017 Protocol Team